Cefixime Capsules

Cefixime is a third-generation oral cephalosporin that kills bacteria by inhibiting bacterial cell wall synthesis. It is stable to most beta-lactamases, and many strains producing penicillinase and cephalosporinase are still sensitive to this product. Cefixime has good antibacterial effects in vitro and in vivo against Gram-positive cocci such as pneumococci, Streptococcus pyogenes, and Gram-negative bacilli such as Haemophilus influenzae (including enzyme-producing strains), Moraxella catarrhalis (including enzyme-producing strains), Escherichia coli, Proteus mirabilis, and Neisseria gonorrhoeae (including enzyme-producing strains). Cefixime also has antibacterial activity against Streptococcus pneumoniae, Parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Pasteurella multocida, Providencia, Salmonella, Shigella, Serratia marcescens, Citrobacter heteromorphis, and Citrobacter malonate, but its clinical effectiveness has not yet been established. This product has poor antibacterial effect on Staphylococcus, and has no antibacterial effect on Pseudomonas aeruginosa, Enterobacter, Bacteroides fragilis, Clostridium, etc.

The main ingredient of this product is cefixime.

This product is a hard capsule. After removing the capsule, the contents are white or light yellow powder.

This product is suitable for the following bacterial infections caused by streptococci (except enterococci) that are sensitive to cefixime, pneumococci, gonococci, catarrhalis, Escherichia coli, Klebsiella, Serratia, Proteus, and influenza bacilli, etc.: 1. Bronchitis, bronchiectasis (when infected), secondary infections of chronic respiratory infections, pneumonia; 2. Pyelonephritis, cystitis, gonococcal urethritis; 3. Cholecystitis, cholangitis; 4. Scarlet fever; 5. Otitis media, sinusitis, etc.

Adults take 400 mg per day, children take 8 mg/kg per day, orally in a single dose or in two divided doses. Children weighing ≥50 kg or aged ≥12 years should take the adult dose. A single dose of 400 mg is appropriate for the treatment of simple gonorrhea. A single dose of 400 mg is appropriate for the treatment of simple gonorrhea. Patients with renal insufficiency whose creatinine clearance (CCr) is 21-60 ml/min and undergoing hemodialysis should be given 50% of the standard dose, i.e. 300 mg per day; patients with CCr ≤20 ml/min and undergoing peritoneal dialysis should be given 50% of the standard dose, i.e. 200 mg per day.

Most of the adverse reactions of cefixime are short-lived and mild. The most common are gastrointestinal reactions, including diarrhea (16%), increased bowel movement (6%), abdominal pain (3%), nausea (7%), indigestion (3%), and abdominal distension (4%); adverse reactions with an incidence rate of less than 2% include rash, urticaria, drug fever, itching, headache, and dizziness. Laboratory abnormalities include transient increases in ALT, AST, ALP, LDH, bilirubin, BUN, and Cr, transient decreases in platelet and white blood cell counts and eosinophilia, and positive direct Coombs test.

Patients with a history of allergy to this product or cephalosporin antibiotics are contraindicated.

Precautions for children: Use with caution in newborns and premature infants. Precautions for pregnancy and lactation: Use with caution in pregnant and lactating women. Precautions for the elderly: Use with caution in elderly patients.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When this product is used in combination with theophylline, competitive inhibition of the binding site of cytochrome P450 may lead to a significant reduction in the liver elimination of theophylline, a prolonged blood elimination half-life (t1/2beta;), an increase in blood drug concentration, and the occurrence of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc., so it should be avoided to use it in combination. If it cannot be avoided, the blood drug concentration of theophylline should be measured and the dose should be adjusted. 3. When cyclosporine is used in combination with this product, its blood drug concentration increases. The blood concentration of cyclosporine must be monitored and the dose adjusted. 4. When this product is used in combination with the anticoagulant warfarin, it can enhance the anticoagulant effect of the latter, so the combination of the two should be avoided. If it cannot be avoided, the patient's prothrombin time should be closely monitored and the dose adjusted. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used in combination, it may cause toxicity due to the increased blood concentration of this product. 6. This product interferes with the metabolism of caffeine, resulting in reduced caffeine elimination, prolonged blood elimination half-life (t1/2beta;), and possible central nervous system toxicity, so the two should be avoided in combination. If it cannot be avoided, the patient's blood caffeine concentration should be closely monitored and the dose adjusted. 7. Acid-free drugs containing aluminum and magnesium can reduce the oral absorption of this product and should not be used in combination. 8. When this product is used in combination with the non-steroidal anti-inflammatory drug fenbufen, convulsions occasionally occur, so it should not be used in combination with fenbufen.

Keep away from light, seal tightly and store in a cool dark place.

100 mg

24 months.

Guangzhou Baiyunshan Pharmaceutical Co., Ltd. Guangzhou Baiyunshan Pharmaceutical General

• Founded in:

  1973-07-01

• Address:

  No. 88, Yunxiang Road, Tonghe Street, Baiyun District, Guangzhou

• Tax NO.:

  91440101714253245D

• Registered Funds:

  -

• Website:

  Log in to view

• Email:

  Log in to view